Thelansis

  Relapsed or refractory Cutaneous T-cell lymphoma (CTCL) refers to a specific type of cancer that affects the skin and is characterized by the proliferation of malignant T-cells, a type of white blood cell. CTCL is a rare form of non-Hodgkin lymphoma and includes several subtypes, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common. Currently, three drugs have gained approval in the United States for treating relapsed or refractory CTCL. These include the oral retinoid known as bexarotene and histone deacetylase inhibitors named romidepsin and vorinostat. Although the response rates to these treatments are typically less than 35%, romidepsin and vorinostat have shown the ability to generate long-lasting responses in patients undergoing extensive prior treatment. The prognosis for patients with relapsed or refractory Cutaneous T-cell lymphoma (CTCL) following therapy is grim, as their overall survival is typically less than a year unless they undergo alloge...